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Two cell-binding domains from FGF-2 (fibroblast
growth factor-2) were shown to increase cell attach-
ment and osteoblastic differentiation. Two synthetic
peptides derived from FGF-2, namely residues 36–41
(F36; PDGRVD) and 77–83 (F77; KEDGRLL), were
prepared and their N-termini further modified for ease
of surface immobilization. Chitosan membranes were
used in the present study as mechanical supportive bio-
materials for peptide immobilization. Peptides could
be stably immobilized on to the surface of chitosan
membranes. The adhesion of mesenchymal stem cells
to the peptide (F36 and F77)-immobilized chitosan
membrane was increased in a dose-dependent manner
and completely inhibited by soluble RGD (Arg-Gly-
Asp) and anti-integrin antibody, indicating the
existence of an interaction between F36/F77 and
integrin. Peptide-immobilized chitosan supported
human bone-marrow-derived mesenchymal-stem-cell
differentiation into osteoblastic cells, as demonstrated
by alkaline phosphate expression and mineralization.
Taken together, the identified peptide-immobilized
chitosan membranes were able to support cell ad-
hesion and osteoblastic differentiation; thus these
peptides might be useful as bioactive agents for osteo-
blastic differentiation and surface-modification tools in
bone regenerative therapy.
Introduction
The application of growth factor to enhance tissue regener-
ation has resulted in good achievements in the field of tissue
engineering and regeneration therapy [1–5]. In particular, the
basic FGF-2 (fibroblast growth factor-2) is of interest as an
important cytokine that induces the early healing process
in bone and cartilage repair [6–8]. rhFGF-2 (recombinant
human FGF-2) has been applied as a bioactive agent for
bone repair in combination with a matrix such as collagen
or demineralized bone [9,10]. The mechanism of FGF-2
involves its binding with an FGFR (FGF receptor), integrin or
proteoglycan on the cell surface [11–16]. Despite its great
potential as a tool for enhancing tissue-healing efficacy in vivo,
clinical applications of controlled growth-factor release are
hindered by two major shortcomings. One is that many of
the growth factors have short biological half-lives. For ex-
ample, when PDGF-BB (platelet-derived growth factor-BB)
or TGF-β1 (transforming growth factor-β1) is intravenously
injected, the compound’s half-life (t½) is less than 10 min
in vivo [4,5]. The use of the peptides in regenerative therapy
might have advantages over using the whole growth factor in
terms of overcoming possible immunogenicity, short t½ and
tumour-related side effects. Peptides can be synthesized on
a large scale, and the N-terminus of these peptides can be
modified for ease of immobilization to present a high density
of peptides. Therefore it was anticipated that the peptide
in combination with biomaterials would provide effective
regeneration capacity while reducing the shortcomings of
whole growth factors. Mechanical supports of these peptides
are required for enhancing cell adhesion, thereby inducing
an early bone-repairing effect. Chitosan is an attractive
biopolymer that has been widely utilized for tissue-repair
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Figure 1 The amino acid sequences of mature FGF-2 across several species
and the amino acid sequences of synthetic peptides
The synthetic peptide sequences in human, murine, rabbit and chicken FGF-2
are highly conserved and are highlighted in grey. F36 consists of six amino acids
corresponding to the sequence between 36 and 41. F77 consists of seven
amino acids corresponding to the sequence between 77 and 83. The two
peptides include an RGD (underlined), and a GGC motif was introduced to
the N-terminus of the peptides to improve the ease of conjugation on the
surface of chitosan membranes. FM36 is a mismatched peptide of F36.
purposes, including bone and cartilage regeneration, and can
be used as a supporting scaffold for cells [17,18]. Chitosan
membrane, in the present study, was modified with the
peptides, and we sought to examine whether the peptide
enhanced the bioactivity of cells on the membrane.
We designed synthetic peptides derived from the
cell-binding domain of FGF-2 that can support cell at-
tachment and differentiation of mesenchymal stem cells
into osteoblastic cells. Two different sequences of binding
motif from FGF-2, F36 (PDGRVD) and F77 (KEDGRLL)
were identified and chemically synthesized. FM36 is a
mismatched peptide of F36 and was used as a control of
F36 in the experiment to demonstrate the importance
of RGD sequence for cell attachment and osteoblastic
differentiation (Figure 1). In the present study, F36 and F77
peptides were immobilized on to the surface of chitosan
membranes using a heterobifunctional cross-linker. Using
hMSCs (human mesenchymal stem cells), we examined
the effect of soluble RGD (Arg-Gly-Asp) and anti-integrin
antibody on cell attachment to the peptide-immobilized
chitosan membrane. Osteoblastic differentiation by immo-
bilized peptide was also demonstrated by ALPase (alkaline
phosphatase) activity and calcium deposition.
Materials and methods
Materials
α-MEM (α-minimal essential medium), DMEM (Dulbecco’s
modified Eagle’s medium), HBSS (Hanks balanced salt solu-
tion), trypsin/EDTA, FBS (fetal bovine serum) and antibiotic/
antimycotic solution were purchased from Gibco BRL
(Grand Island, NY, U.S.A.). BSA was purchased from Sigma
(St. Louis, MO, U.S.A.). The antibodies that block α1–α6
and β1 integrin function (β1 Integrin Partners Investigator
kit) were purchased from Chemicon (Temecula, CA,
U.S.A.). Other chemicals were obtained from Sigma.
Peptide synthesis
All peptides (Figure 1) were manually synthesized by the
Fmoc (fluoren-9-ylmethoxycarbonyl) strategy using a pep-
tide synthesizer (APEX 396; AAPP TEC, Louisville, KY,
U.S.A.) and were prepared in the C-terminal amide form as
described previously [19]. Amino acid derivatives and resins
were purchased from AAPP TEC. The respective amino
acids were condensed manually in a stepwise manner us-
ing 4-(2′,4′-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy
resin. N-dimethylformamide was used during the synthesis as
a solvent. The resulting crude peptides were precipitated and
washed with diethyl ether and were then purified by reverse-
phase HPLC (using a Vydac C8 column and a gradient of
water/acetonitrile containing 0.1% trifluoroacetic acid). The
purity of each peptide was above 90%.
Immobilization of peptides
The amount of immobilized peptide on the well plates was
investigated by the method of Park et al. [20] with some
modifications. The peptides were labelled with FITC
at their N-termini [21]. Chitosan (98% deacetylated;
molecular mass 300 kDa; Sigma) membranes were prepared
by casting 2% (w/v) solution of chitosan in 2% acetic
acid into non-tissue-culture plates (500 μl per well for
24 wells and 100 μl per well for 96 wells). Chitosan
membranes were air-dried for 2 days, then neutralized
with 0.1 M NaOH for 1 h, then washed with doubly
distilled water until the pH was neutral. The chitosan
membrane was allowed to react with SMCC [succinimidyl
4-(N-maleimidomethyl)cyclohexane-1-carboxylate; 50 mM;
Pierce] for 4 h to activate the amine groups in the chitosan.
Various concentrations of FITC–peptide in PBS (pH 7.4)
were added to the SMCC-linked chitosan and the reaction
was allowed to take place at 4 ◦C overnight and the chitosan
then washed three times with 8 M urea and PBS to remove
unchanged peptides. The absorbance of FITC–peptide was
detected at 494 nm using a microplate reader (BioTek,
Winooski, VT, U.S.A.) [22]. The standard curve was then
used to immobilize peptide with input concentration of
peptide solutions for the 96-well plates. The plates were
coated with 100 μl of 2% (w/v) BSA in PBS for 1 h, and
then washed with PBS. These plates were then employed
for the cell-adhesion and inhibition studies described below.
Cell culture
Human bone-marrow aspirates were obtained during
pelvic osteotomy after obtaining informed consent and the
approval of the IRB (Institutional Review Board) of KNIH
(Korean National Institute of Health) and Seoul National
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University. hMSCs were isolated from three patients (aged
23–40 years) as described previously [23] and plated in T75
flasks for continuous passaging in DMEM supplemented with
20% (v/v) FBS (Gibco BRL) and 1% antibiotic/antimycotic
solution (Gibco BRL). The medium was changed twice
weekly and cells were detached using trypsin/EDTA and
passaged into fresh culture flasks at a ratio of 1:4 on
reaching confluence. Cultures were incubated at 37 ◦C
under a humidified atmosphere containing 95% air and 5%
CO2. Overall procedure for obtaining cells from patients
was approved by both the IRB of KNIH and the IRB of
Seoul National University Dental Hospital.
Cell adhesion assay
The cell-adhesion assay was performed by the method of
Mochizuki et al. [19]. Cells (1 × 104 cells per well) were
allowed to adhere for 3 h at 37 ◦C in serum-free α-MEM con-
taining 0.1% BSA. Attached cells were fixed with 4% (w/v)
paraformaldehyde and incubated in 0.2% Crystal Violet dye
for 15 min. Wells were washed thoroughly with distilled
water and the Crystal Violet dye was extracted with 2%
(w/v) SDS solution. Then, the A540 of each well was measured
using a microplate reader (BioTek). The absorbance of
the Crystal Violet solution from the BSA-coated chitosan
membrane without peptide treatment served as the control,
and the A540 of the BSA-coated well was set to 0%. The
percentage of adherent cells was determined by using the
following equation:




absorbance of Crystal Violet solution
from peptide-immobilized chitosan
absorbance of Crystal Violet




To examine the change in attachment due to the addi-
tion of RGD or heparin, 1 mM RGD or 20 μg/ml heparin was
added to the cell suspensions before the cells were seeded
on to the well, and the absorbance of the cultured wells
was measured as described above. In addition, the effect
of an integrin-binding antibody on cellular attachment was
examined as described above, except for pretreatment with
a functional integrin-blocking antibody (10 μg/ml) for 30 min
at 37 ◦C, with vortex-mixing every 5 min before plating.
After 3 h of incubation, the attached cells were quantified
as described above. All assays were performed in triplicate,
with each experiment repeated at least three times.
Actin cytoskeleton of cultured cells
The 100-μM-peptide-immobilized chitosan in four-well Lab-
Tek II Chamber Slides (Nalgen Nunc International,
Naperville, IL, U.S.A.) were prepared by the same method
as described above. Then, hMSCs (1 ml, 1 × 104 cells) were
added and incubated at 37 ◦C for 3 h. Cells were fixed with
4% formaldehyde in PBS for 10 min and permeabilized for
5 min with 0.1% Triton X-100 in PBS. Cells were blocked
for 1 h with 1% BSA in PBS and incubated with anti-vinculin
antibodies (Sigma–Aldrich) diluted 1:400 in 1% BSA/PBS for
1 h, followed by incubation for another 1 h with the mixture
of Alexa Fluor® 546-conjugated goat anti-mouse secondary
antibody (4 μg/ml; Molecular Probes, Eugene, OR, U.S.A.)
and Alexa Fluor® 488-conjugated phalloidin (0.67 unit/ml;
Molecular Probes) in 0.1% BSA/PBS according to the manu-
facturer’s protocol. Nuclear staining was conducted with
Hoechst 33342 (5 μg/ml, Molecular Probes) according to
the manufacturer’s protocol. Coverslips were mounted on
to slips using ProLong Gold (Molecular Probes). The images
of cells in each peptide-treated well were acquired using an
Olympus FV-300 laser scanning microscope operated with
FLUOVIEW software (Olympus, Tokyo, Japan).
Osteogenic differentiation
The 100-μM-peptide-immobilized chitosan membranes in
24-well plates (Nalgen Nunc International) were prepared
by the same method as described above. To examine the
osteogenic differentiation of cells, the hMSCs (1 × 104 per
well) were cultured under an osteogenic medium (α-MEM
containing 15% FBS, 1% antibiotic/antimycotic solution,
10 mM sodium β-glycerol phosphate, 50 μg/ml L-ascorbic
acid and 10−7 M dexamethasone) for 14 days. The medium
was changed twice a week. The ALPase activity was meas-
ured by fixing cultured cells with 4% (w/v) paraformaldehyde
and staining them with a mixed solution of naphthol and Fast
Red Violet according to the manufacturer’s instructions for
the ALP (alkaline phosphate) staining kit (Chemicon). The
level of ALPase activity was also measured spectroscopically.
After 14 days of culture, cells were washed with PBS, treated
with 2.5% trypsin in 4 mM EDTA to detach cells, and
centrifuged at 70 g for 5 min. The cells were sonicated
on ice (Sonic dismembrator 550; Fisher, Pittsburgh, PA,
U.S.A.) for 1 min at 110 W (50/60 Hz). Aliquots of the
cells were incubated with 0.1 M of glycine/NaOH buffer,
15 mM of p-nitrophenyl phosphate solution and 0.1% Triton
X-100/saline at 37 ◦C for up to 30 min. The reaction was
quenched by adding 0.1 M NaOH and placing the mixture
on ice. The production of p-nitrophenol in the presence of
ALPase was measured by monitoring the absorbance of the
solution at a wavelength of 405 nm. Protein concentrations
of the cell lysates were determined by the Bradford protein
assay (Bio-Rad Laboratories, Hercules, CA, U.S.A.). ALPase
activity is expressed as nmol of p-nitrophenol released/min
per mg of protein.
The calcium phosphate precipitates from the cell
cultures were stained using Alizarin Red S, as described
elsewhere [19]. In brief, the cultured cells were fixed with
95% ethanol (4 ◦C, 15 min), washed with deionized water,
and then treated with 2% Alizarin Red S (Sigma) for 10 min.
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The wells were washed several times with deionized water
to remove the unbound stain and photographed using an
Olympus inverted microscope. The calcium content in
the cell lysates were measured according to a previously
published method using Sigma diagnostic kit no. 587-A [24],
which measures the amount of purple-coloured calcium–
OCPC (o-cresolphthalein complexone) complex formed as a
result of binding between OCPC and free calcium generated
by cells. A 0.5 ml portion of the lysates was incubated at
room temperature (25 ◦C) overnight with 0.5 ml of acetic
acid (1.0 M) in order to extract calcium from mineralized
constructs. A 10 μl portion of the samples was taken and
placed in a 96-well plate. Equal amounts (150 μl) of calcium-
binding reagent (OCPC, 0.24% 8-hydroxyquinoline and
surfactant) and calcium buffer reagent (500 mM 2-amino-2-
methylpropane-1,3-diol) supplied with the kit were added to
each well, and the plate was incubated at room temperature
for 10 min. The standards in concentrations ranging from 5
to 100 μg/ml were prepared using CaCl2. The attenuance
of each well was measured using a microplate reader
at 575 nm. The calcium content from each sample was
normalized to the total protein, determined by the Bradford
protein assay (Bio-Rad Laboratories), at each time point.
Statistical analysis
All values are presented as the means +− S.E.M. for all control
and experimental data (n = total number of independent
cultures). Data were analysed by one-way ANOVA followed
by Fisher’s PLSD (protected least-squares difference) post
hoc test (StatView; SAS Institute, Cary, NC, U.S.A.). A P
value of <0.05 was considered significant.
Results and discussion
Immobilization of peptide on to the chitosan
membrane
Synthetic and natural biomaterials have been utilized clini-
cally in tissue-regenerative procedures. Chitosan, which is a
co-polymer of N-acetylglucosamine and glucosamine and is
obtained from chitin through its deacetylation, is now well
known for its numerous and interesting biological properties
as a biocompatible, bioresorbable and bioactive polymer
[17,25]. However, these materials alone are less bioactive
towards cells in vivo; thus the surface immobilization
approach using growth factors has been of interest to the
medical and pharmaceutical community to increase the bio-
logical activity of the materials [20]. However, the application
of growth factors itself has been beset by limitations,
including a short t½ in vivo as well as side effects caused
by overdoses to compensate for the short t½ [26–30].
Therefore it would be useful to have stable peptides with
long-lasting activity that would have a direct effect on cells
at the applied site of injury. By modifying the surface with
Figure 2 Immobilization of FITC-labelled peptide on the surface of chitosan
membranes in accordance with the concentration of the initial amount of
applied peptide (10, 50, 100, 150 and 200 μM)
Surface-immobilized peptide was measured as described in the Materials
and methods section. Results were obtained from three sets of separate
experiment with at least four samples (n = 4) and are expressed as
means +− S.E.M.
FGF-2-derived synthetic peptides, these workers attempted
to generate a biomimetic surface for tissue regeneration.
Peptide-modified surfaces promoted cell attachment and
osteoblastic differentiation with sequence-specific activity
in vitro, implying the peptides’ usefulness in preparing
surface-active biomaterials for tissue engineering.
Various RGD peptides were coated on titanium, silk,
hydroxyapatite and polymer to promote cell functions such
as attachment and differentiation [31–34]. Most RGD pep-
tides were identified from extracellular-matrix components
such as fibronectin and bone sialoprotein [35,36]. Two
inverse sequences of the RGD cell-adhesive domains in FGF-
2 were identified in a previous study [14]. However, the
present study demonstrated that whole FGF-2 interacts with
ανβ3 integrin, and this interaction mediates the capacity
of the angiogenic growth factor to induce adhesion and
mitogenesis of endothelial cells. The RGD sequence is
present in FGF-2, but the effects of those sequences on bone
regeneration have not yet been demonstrated. Therefore we
synthesized peptides F36 and F77, which contain the RGD
sequence, and we investigated the biological activity on the
osteoblastic differentiation of hMSC by F36 and F77.
Two bioactive peptides (F36 and F77) were synthesized
using Fmoc (fluoren-9-ylmethoxycarbonyl) chemistry with
a C-terminal amide, whereas the N-terminus was further
modified with a spacer dipeptide (Gly-Gly) and cysteine for
ease of further modification. The thiol functional group of
cysteine was chemically immobilized on the amine group
of chitosan by forming S–S bond through SMCC. The im-
mobilization efficiency of peptide on plates was approx. 70%
of initial peptide concentration (10–100 μM) and decreased
to 60% at 200 μM (Figure 2). The immobilized peptide
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Figure 3 Effects of peptides on hBMSC adhesion
The cells were allowed to attach to F36-, F77- and FM36-immobilized chitosan
membranes for 3 h and then were stained with Crystal Violet and detected
as described in the Materials and methods section. The extent of adherent
cells on the peptide-immobilized chitosan membranes was determined by
measuring A540 and was expressed as a percentage of the absorbance measured
in BSA-coated chitosan membrane. Results are presented as means +− S.E.M. for
the control and for each concentration of peptide, and triplicate experiments
were performed (n is at least 4). Symbols: , F36; , F77; , FM36.
*Significantly different from the control (cells on the FM36-immobilized
chitosan membranes; P<0.05).
on chitosan membrane was not increased in proportion
to input of peptide above 100 μM; therefore we used
100-μM-peptide-immobilized chitosan membranes in the
in vitro test. To compensate for the decreased efficiency,
excess concentration of peptide solution was applied to
the well plates to reach the 100 μM peptide concentration,
which was confirmed by quantification, as described in
the Materials and methods section, of immobilization of
peptide. The peptide concentration used in the cell-culture
experiment was that of the immobilized peptide.
Cell adhesion on peptide-immobilized surface
The mismatching sequence of F36, termed as FM36, was
used as a control for these peptides, whereas 1% BSA-
coated chitosan membrane served as a negative control.
The hMSCs were used to evaluate the cell-adhesion
activity of the peptide. As seen in Figure 3, the peptides
induced higher cell attachment in sharp contrast with
the mismatched peptide (FM36), which showed poor
cell attachment. F36 and F77 presented increased cell
attachment in accordance with the concentrations of
peptide, showing a saturation of the cell attachment level at
Figure 4 Morphology of attached hMSCs on a peptide-immobilized chitosan membranes
F36, F77 and FM36 (100 μM) were immobilized as described in the Materials and methods section. Cells were incubated for 3 h on each peptide and then were
fixed and stained for actin (green), focal adhesion (red) and nucleus (blue). Actin stress fibres were visualized with phalloidin, focal adhesion was visualized with
vinculin, and the nucleus was visualized with Hoechst 33342.
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concentrations above 100 μM. The mismatching sequence,
however, attenuated the adhesive activity of the F36 peptide
towards cells, indicating that the sequences of F36 and F77
were specific cell-binding regions of FGF-2. The number
of cells adherent to the peptide-immobilized surface was
specific to the sequence and also depended on the amount
of applied peptide. FM36 significantly reduced cell-adhesive
activity when compared with F36, indicating that the cell
surface specifically recognizes peptide sequences of F36.
Cell morphology
We compared the organization of the cytoskeleton of
hBMSCs (human bone-marrow-derived mesenchymal
stem cells) attached on the peptide-immobilized chitosan
membrane by staining with vinculin and phalloidin to
visualize focal adhesion and actin stress fibres respectively
(Figure 4). Cells cultured on the BSA-coated chitosan
served as controls and showed unspread shapes with poor
microfilament bundles. The FM36 showed little actin stress
fibre and no focal-adhesion complex in the cell membrane
although it seemed to be having a more spread morphology
than BSA-coated wells. The difference in morphology be-
tween BSA and FM36 was not so significant; thus FM36
could not support the cell attachment. However, in contrast
with the control, F36 and F77 induced the shapes typical
of actin stress fibre as well as vinculin-containing focal
adhesion at the end of actin stress fibres (Figure 4). In the
cell attachment test, we use the cell culture medium without
FBS, which promotes cell attachment, to demonstrate the
activity of peptide for cell attachment. The presence of RGD
sequence in F36 and F77 enhanced cell attachment in short
incubation times. The focal-adhesion and actin-stress-fibre
formation in the cells also confirms that integrin may be
involved in the cell adhesion to the peptides.
Interaction of peptide with cell surface molecules
We next evaluated the effect of RGD and heparin on the
hMSCs’ attachment to the peptide-immobilized chitosan
membranes. Cell adhesion to the peptides F36 and F77 was
inhibited by soluble RGD, but not by heparin (Figure 5A).
RGD-dependent cell adhesion of hMSCs was studied
through inhibition of cell adhesion assays using soluble RGD
peptides as inhibitors [37]. If the cell adhesion interfered
with heparin, this means the peptides bind to cell-surface
heparan sulfate proteoglycans [38,39]. This result indicates
that the cells attached to F36 and F77 in an RGD-dependent
manner, suggesting integrin-mediated cell adhesion.
Antibody-blocking experiments were conducted
to verify the type of integrin subunit that the peptides
recognize (Figure 5B). The hMSCs express several integrin
subunits including α1, α2, α3, α5, α6 and β1 [40]. As
peptides F36 and F77 contain an RGD sequence, an
Figure 5 Effects of RGD and heparin (A) and integrin-blocking antibodies
(B) on cell attachment to peptides
(A) The effect of RGD and heparin on cell attachment to peptides. F36, F77
and FM36 (100 μM) were immobilized on chitosan membranes as described in
the Materials and methods section. The hMSCs were allowed to attach to the
peptides in the absence or presence of 1 mM RGD or 20 μg/ml heparin added
to the cell suspensions, and then the cells were plated. After 3 h of incubation,
the attached cells were assayed by Crystal Violet staining. The results were
obtained from at least three similar experiments, and means +− S.E.M. are
indicated (n is at least 4). *Significantly different from control (cells that were
not treated with RGD or heparin; P<0.05). (B) Effect of integrin-blocking
antibodies on cell attachment to peptides. F36, F77 and FM36 (100 μM) were
immobilized on chitosan membranes as described in the Materials and methods
section. The hMSCs were allowed to attach to the peptides in the absence
or presence of integrin-blocking antibodies added to the cell suspensions, and
then the cells were plated. After 3 h of incubation, the attached cells were
assayed by Crystal Violet staining. The results were obtained from at least
three similar experiments, and means +− S.E.M. are indicated (n is at least 4).
*Significantly different from control (IgG-treated cells; P < 0.05). Symbols: ,
F36; , F77; , FM36.
antibody specific to integrin partially blocked adhesion to
these peptides. Among antibodies against α1–α6 and β1,
antibodies against α3, α5 and β1 showed inhibition effect
C© 2009 Portland Press Ltd
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Figure 6 Effects of peptides on osteoblastic differentiation and matrix mineralization
(A) F36, F77 and FM36 (100 μM) were immobilized on chitosan membranes as described in the Materials and methods section, and hMSCs were cultured for
14 days. The ALP expression and mineralized matrix were visualized by ALP staining and Alizarin Red S staining respectively. (B) Measurement of calcium deposition
and the ALP activity. The experiment was performed three times. *Significantly different from control (cells on the no-peptide-immobilized well; P<0.05).
on cell attachment to F36 and F77. The blocking antibodies
against α3, α5 and β1 integrin subunits inhibited cell
adhesion to the F36 peptide by 60, 50 and 50% respectively.
Antibodies against α5 and β1 reduced adhesion to F77 by
70 and 50 %. FM36 was not affected by the presence of
antibodies against α3, α5 and β1. The inhibition of adhesion
to peptides F36 and F77 by the addition of RGD and
integrin antibodies demonstrated that integrin on the cell
surfaces may be recognized by the peptides F36 and F77.
Osteogenic differentiation and mineralization
Figure 6(A) shows the expression of ALPase and
mineralization in the cells on the F36- and F77-immobilized
chitosan membranes. The ALPase enzyme is often used
as a marker for increased osteoblastic metabolic activity
and an early indicator of osteoblastic differentiation [41].
The expression was apparent in the cells cultured on F36-
and F77-immobilized chitosan membranes. Cells treated
with the mismatched peptide (FM36) did not display any
significant ALPase expression, indicating the sequence-
specific activity of the peptides. In vitro matrix mineralization
was examined as an end-point indicator of the osteoblastic
phenotype and the ultimate demonstration of the activity of
F36 and F77 (Figure 6A). Enhanced mineralization was seen
for cells cultured on the F36- and F77-immobilized chitosan
membranes, in sharp contrast with either those cultured
on the mismatched-peptide- or no-peptide-immobilized
chitosan membranes. These results also demonstrate that
the presence and the activity of immobilized peptides were
maintained for 14 days in culture medium under cell culture
conditions. When osteoblastic cells are cultured in vitro, min-
eralization, an indicator of late osteoblastic differentiation,
occurs after 28 days [2,42]. Therefore, by using peptides,
the time for differentiation could be shortened to 14 days.
The levels of ALPase activity and calcium were quanti-
fied and are shown in Figure 6(B), indicating that the peptide
immobilized to the cells raises ALPase and mineralization
induction, as compared with the cells on the no-peptide-
immobilized chitosan, by 3–3.5-fold. The two peptides are
sufficient to drive hMSCs into osteogenic differentiation, and
they can be developed as therapeutic tools for bone regen-
eration. The number of glycine residues in the N-terminus
of F36 and F77 can be modified to change the bioactivity
of peptides. The N-terminus of the peptides can be further
modified by introducing another sequence, and this makes
it possible to immobilize the peptides on to biomate-
rials. It is beneficial to maintain the activity of the peptides for
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a longer time by prolonging their presence on the surface of
biomaterials. A major finding of the present study is that the
peptides derived from the RGD domain of FGF-2 had good
cell-attachment activity and osteogenic differentiation capa-
city. These peptides can be applied to biomaterials for tissue
engineering to provide a bioactive/bioadhesive surface.
Conclusions
Two synthetic cell-binding peptides, F36 and F77, were
immobilized on the chitosan membranes and tested for bio-
logical activity on osteoblast differentiation. They increased
cell attachment in a dose-dependent manner by interaction
with cell-surface integrin. Furthermore, the peptides
supported the differentiation of hBMSCs into osteoblastic
cells, as demonstrated by ALPase activity and mineralization.
Taken together, the cell-binding peptides from FGF-2 could
be applied on the surface of biomaterials for enhanced
osteoblastic differentiations and bone regeneration.
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